Journal Article
|ResearchMultidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients
Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bayona J, Becerra M, Benedetti A, Burgos MV, Centis R, Chan ED, Chiang C, Cox HS, DAmbrosio L, DeRiemer K, Huy Dung N, Enarson D, Falzon D, Flanagan K, Flood J, Garcia-Garcia M, Gandhi N, Granich R, Hollm-Delgado M, Holtz TH, Iseman M, Jarlsberg L, Keshavjee S, Kim HJ, Koh WJ, Lancaster J, Lange C, de Lange W, Leimane V, Leung CC, Li J, Menzies D, Migliori GB, Mishustin S, Mitnick CD, Narita M, ORiordan P, Pai M, Palmero D, Park S, Pasvol G, Pena J, Perez-Guzman C, Quelapio M, Ponce-de-Leon A, Riekstina V, Robert J, Royce S, Schaaf HS, Seung KJ, Shah L, Shim TS, Shin S, Shiraishi Y, Sifuentes-Osornio J, Sotgiu G, Strand M, Tabarsi P, Tupasi T, van Altena R, Van der Walt M, Van der Werf T, Vargas M, Viiklepp P, Westenhouse J, Yew WW, Yim JJ
Abstract
Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic, expensive, and has generally poor outcomes. We undertook an individual patient data meta-analysis to assess the impact on outcomes of the type, number, and duration of drugs used to treat MDR-TB.
Countries
Subject Area
Languages
English
